Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1013 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-07-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the clinical effectiveness and safety of adalimumab as used in routine clinical practice in adult participants with moderate to severe rheumatoid arthritis (RA) in Canada.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

NCT01078090

Rheumatoid Arthritis

COMPLETED

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

NCT01077258

Rheumatoid Arthritis

COMPLETED

Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis

NCT01076959

Rheumatoid Arthritis

COMPLETED

Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis

NCT00234897

Rheumatoid Arthritis

COMPLETED PHASE4

Optimization of Treatment With Adalimumab (Humira)

NCT01585064

Rheumatoid Arthritis (RA)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

REACH is an observational survey of participants with moderate to severe rheumatoid arthritis taking adalimumab. Participants who volunteer will be asked to provide information about their medical history and experiences with adalimumab. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Moderate-to-severe Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moderate-to-severe rheumatoid arthritis

Participants with moderate-to-severe rheumatoid arthritis treated with adalimumab in routine clinical practice

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is eligible to take part in the registry as per the product monograph.
* Participants that are naïve to adalimumab therapy / or participants that have been receiving adalimumab therapy for less than 4 months.
* Participant has moderately to severely active RA.
* Participant who has had an inadequate response to one or more Disease Modifying Anti-Rheumatic Drugs (DMARDs).
* Participant received provincial or private (insurance companies) approval for adalimumab.
* Participant is able to give written informed consent and to understand the survey requirements.

Exclusion Criteria

* Participant to whom a traditional DMARD had never been tried.
* Participant with a known hypersensitivity to adalimumab, or any of its components.
* Participant is receiving free adalimumab as part of a compassionate program or an early access drug distribution program.
* Participant with clinically significant concurrent medical or psychiatric disorders that may influence survey outcomes.
* Participant with any condition that would prevent participation in the survey and completion of the survey procedures including language limitation or possibility that the participant will not be available for a period of time (\> 12 months) while being enrolled in the survey.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No